On July 31, DexCom rose 6.65% in pre-market trading, trading at $79.3 per share. The stock surged after the company reported second-quarter results that comprehensively exceeded market expectations and raised its full-year revenue guidance.

Driven by robust demand for its continuous glucose monitoring systems, DexCom posted Q2 adjusted earnings of $0.70 per diluted share, beating the analyst consensus estimate of $0.61 by 14.75% and representing a 45.83% increase from $0.48 in the year-ago period. Revenue reached $1.308 billion, up approximately 13% year-over-year and above the $1.29 billion analyst estimate. The company also raised its full-year revenue outlook to $5.18 billion-$5.25 billion, lifting the prior lower bound from $5.16 billion, versus the FactSet consensus of $5.22 billion.

Analysts remain broadly constructive on DexCom, with Goldman Sachs maintaining a Buy rating and a mean price target of approximately $82.48. RBC Capital Markets has highlighted Medicare CGM coverage as the biggest catalyst ahead, noting U.S. CGM penetration remains around 30% of covered lives.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)